Recent Updates
Recently added Catalysts

ZP9830

Phase 1

Plaque Psoriasis | Small molecule | Dermatology |Icon Plc|Last Updated: Jul 29, 2026

Development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Jul 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment32

FDA Designations

No designations recorded

Clinical trial landscape

ZP9830 · 1 trial · 1 indication

Phase 1 1
NCT07733089A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment PeriodPlaque Psoriasis
RECRUITING32 Analytics
PHASE1RECRUITING
A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period
Plaque Psoriasis
NCT0773308932
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Treatment Emergent Adverse Events (TEAEs)
From baseline (Day 1, predose) to follow-up (Day 85)

To evaluate the safety and tolerability of ZP9830 following administration of multiple doses in participants with plaque psoriasis.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ZP9830EXPERIMENTALThe experimental arm is divided into two treatment arms with different dose frequencies.
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
ZP9830DRUGParticipants will receive multiple doses of ZP9830. The dose frequency will depend on treatment arm
PlaceboDRUGParticipants will receive multiple doses of placebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Participants with a confirmed diagnosis of psoriasis (stable plaque psoriasis ≥ 2 months). * Participants who have ≥ 2 vulgar psoriatic plaques. * BMI within the range 18.0-35.0 kg/m2 (inclusive). * Further inclusion criteria apply. Exclusion Criteria: * Erythrodermic, predo...

Countries:Netherlands
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Icon Plc (ICLR)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ZCompanies A to ZEvery biotech and pharma company we track